Acuta Capital Partners is an investment fund managing more than $119 billion ran by Scott Smith. There are currently 31 companies in Mr. Smith’s portfolio. The largest investments include Ocular Therapeutix Inc and Enliven Therapeutics Inc, together worth $28.2 billion.
As of 7th August 2024, Acuta Capital Partners’s top holding is 2,771,130 shares of Ocular Therapeutix Inc currently worth over $19 billion and making up 16.0% of the portfolio value.
Relative to the number of outstanding shares of Ocular Therapeutix Inc, Acuta Capital Partners owns more than approximately 0.1% of the company.
In addition, the fund holds 397,698 shares of Enliven Therapeutics Inc worth $9.29 billion.
The third-largest holding is Vaxcyte worth $8.34 billion and the next is Dyne Therapeutics worth $7.5 billion, with 212,500 shares owned.
Currently, Acuta Capital Partners's portfolio is worth at least $119 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Acuta Capital Partners office and employees reside in Redwood City, California. According to the last 13-F report filed with the SEC, Scott Smith serves as the Chief Operating Officer at Acuta Capital Partners.
In the most recent 13F filing, Acuta Capital Partners revealed that it had opened a new position in
Corbus Pharmaceuticals Holdi and bought 64,500 shares worth $2.92 billion.
The investment fund also strengthened its position in Ocular Therapeutix Inc by buying
135,843 additional shares.
This makes their stake in Ocular Therapeutix Inc total 2,771,130 shares worth $19 billion.
Ocular Therapeutix Inc soared 79.4% in the past year.
On the other hand, there are companies that Acuta Capital Partners is getting rid of from its portfolio.
Acuta Capital Partners closed its position in Applied Therapeutics on 14th August 2024.
It sold the previously owned 792,000 shares for $5.39 billion.
Scott Smith also disclosed a decreased stake in Rocket Pharmaceuticals Inc by 0.2%.
This leaves the value of the investment at $5.39 billion and 250,370 shares.
The two most similar investment funds to Acuta Capital Partners are Dc Investments Management and Duncan Williams Asset Management. They manage $119 billion and $119 billion respectively.
Acuta Capital Partners’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 61.0% of
the total portfolio value.
The fund focuses on investments in the United States as
51.6% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
13% of the total holdings value.
On the other hand, large-cap stocks make up only 3.2% of the portfolio.
The average market cap of the portfolio companies is close to $1.45 billion.
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Ocular Therapeutix Inc |
5.15%
2,771,130
|
$18,954,529,000 | 15.98% |
| Enliven Therapeutics Inc |
0.40%
397,698
|
$9,294,202,000 | 7.84% |
| Vaxcyte, Inc. |
5.31%
110,400
|
$8,336,304,000 | 7.03% |
| Dyne Therapeutics, Inc. |
15.18%
212,500
|
$7,499,125,000 | 6.32% |
| Praxis Precision Medicines I |
1.31%
164,431
|
$6,800,866,000 | 5.73% |
| Crinetics Pharmaceuticals Inc |
72.37%
135,141
|
$6,052,965,000 | 5.10% |
| Rocket Pharmaceuticals Inc |
23.38%
250,370
|
$5,390,466,000 | 4.54% |
| Applied Therapeutics, Inc. |
Closed
792,000
|
$5,385,600,000 | |
| Taysha Gene Therapies, Inc. |
30.07%
2,330,937
|
$5,221,299,000 | 4.40% |
| Revolution Medicines Inc |
7.50%
133,000
|
$5,161,730,000 | 4.35% |
| Insmed Inc |
16.82%
72,100
|
$4,830,700,000 | 4.07% |
| Disc Medicine Inc |
Closed
76,800
|
$4,781,568,000 | |
| Celldex Therapeutics Inc. |
Closed
109,000
|
$4,574,730,000 | |
| Sarepta Therapeutics Inc |
57.14%
27,500
|
$4,345,000,000 | 3.66% |
| Hillevax Inc |
Closed
250,609
|
$4,167,628,000 | |
| Tourmaline Bio Inc |
3.26%
269,614
|
$3,467,236,000 | 2.92% |
| Agios Pharma |
42.41%
78,700
|
$3,393,544,000 | 2.86% |
| Kura Oncology Inc. Common Stock |
81.11%
163,000
|
$3,356,170,000 | 2.83% |
| Mersana Therapeutics Inc |
23.17%
1,663,000
|
$3,342,630,000 | 2.82% |
| Immunovant Inc |
Closed
92,346
|
$2,983,699,000 | |
| Corbus Pharmaceuticals Holdi |
Opened
64,500
|
$2,918,625,000 | 2.46% |
| Aadi Biosciences Inc |
No change
1,849,402
|
$2,700,127,000 | 2.28% |
| Viridian Therapeutics Inc |
No change
199,433
|
$2,594,623,000 | 2.19% |
| Terns Pharmaceuticals Inc |
20.60%
369,280
|
$2,514,797,000 | 2.12% |
| Verastem Inc |
Closed
207,095
|
$2,443,721,000 | |
| Mereo Biopharma Group Pl-adr |
70.15%
677,000
|
$2,437,200,000 | 2.05% |
| Arcellx Inc |
22.32%
42,200
|
$2,329,018,000 | 1.96% |
| Helix Acquisition Corp Ii |
Opened
177,836
|
$1,817,484,000 | 1.53% |
| Argenx Se |
Opened
4,000
|
$1,720,160,000 | 1.45% |
| Lyra Therapeutics, Inc. |
Closed
173,320
|
$1,078,050,000 | |
| Ultragenyx Pharmaceutical Inc. |
Closed
20,000
|
$933,800,000 | |
| Intra-Cellular Therapies Inc |
Closed
13,300
|
$920,360,000 | |
| Trevi Therapeutics, Inc. |
Opened
260,000
|
$774,800,000 | 0.65% |
| Celcuity Inc |
Opened
45,000
|
$737,100,000 | 0.62% |
| Oric Pharmaceuticals, Inc. |
7.69%
96,000
|
$678,720,000 | 0.57% |
| Pliant Therapeutics, Inc. |
Opened
46,200
|
$496,650,000 | 0.42% |
| Rapport Therapeutics Inc |
Opened
20,000
|
$465,200,000 | 0.39% |
| Newamsterdam Pharma Co Nv |
Opened
22,500
|
$432,225,000 | 0.36% |
| Leap Therapeutics Inc |
44.94%
195,000
|
$382,200,000 | 0.32% |
| Cellectar Biosciences Inc |
50.87%
70,500
|
$176,250,000 | 0.15% |
| No transactions found | |||
| Showing first 500 out of 40 holdings | |||